^Clinical trial number NCT03071133 for "Asunaprevir/Daclatasvir/Beclabuvir Fixed-Dose Combination Safety Surveillance in Japanese Patients With Chronic Hepatitis C (HCV) or Japanese Patients With Compensated Cirrhosis" at ClinicalTrials.gov
^Clinical trial number NCT02124044 for "Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV" at ClinicalTrials.gov
^Ahmed AM, Doheim MF, Mattar OM, Sherif NA, Truong DH, Hoa PT, et al. Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis. Journal of Medical Virology. May 2018, 90 (5): 907–918. PMID 28892235. S2CID 3829214. doi:10.1002/jmv.24947.
^Tatum H, Thuluvath PJ, Lawitz E, Martorell C, DeMicco M, Cohen S, et al. A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1. Journal of Viral Hepatitis. August 2015, 22 (8): 658–64. PMID 25496007. doi:10.1111/jvh.12372.